Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020;323:844–53.
Article
PubMed
PubMed Central
Google Scholar
Attwood MM, Rask-Andersen M, Schiöth HB. Orphan drugs and their impact on pharmaceutical development. Trends Pharmacol Sci. 2018;39:525–35.
Article
CAS
PubMed
Google Scholar
Hughes DA, Poletti-Hughes J. Profitability and market value of orphan drug companies: a retrospective, propensity-matched case–control study. PLoS One. 2016;11:e0164681.
Article
PubMed
PubMed Central
Google Scholar
European Medicines Agency-EMA. 2021. https://www.ema.europa.eu/en/glossary/well-established-use. Accessed 18 June 2021.
Toumi M, Rémuzat C. Value added medicines: what value repurposed medicines might bring to society? J Mark Access Health Policy. 2017;5:1264717.
Article
PubMed
Google Scholar
Lin S, Chan G, Palczewski K, Lewis K. Drug Repurposing: The New R&D. 2017. https://www.researchgate.net/publication/320877009_Drug_Repurposing_The_New_RD. Accessed 18 Mar 2021.
Petykó ZI, Inotai A, Holtorf AP, Brixner D, Kaló Z. Barriers and facilitators of exploiting the potential of value-added medicines. Expert Rev Pharmacoecon Outcomes Res. 2020;20:229–36.
Article
PubMed
Google Scholar
Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41–58.
Article
CAS
PubMed
Google Scholar
Petykó ZI, Kaló Z, Espin J, Podrazilová K, Tesar T, Maniadakis N, et al. Development of a core evaluation framework of value-added medicines: report 1 on methodology and findings. Cost Eff Resour Alloc. 2021 (manuscript under review).
Phelps CE, Lakdawalla DN, Basu A, Drummond MF, Towse A, Danzon PM. Approaches to aggregation and decision making-a health economics approach: an ISPOR special task force report [5]. Value Health. 2018;21:146–54.
Article
PubMed
PubMed Central
Google Scholar
Kolasa K, Zwolinski KM, Zah V, Kaló Z, Lewandowski T. Revealed preferences towards the appraisal of orphan drugs in Poland—multi criteria decision analysis. Orphanet J Rare Dis. 2018;13:67.
Article
PubMed
PubMed Central
Google Scholar
Iskrov G, Miteva-Katrandzhieva T, Stefanov R. Multi-criteria decision analysis for assessment and appraisal of orphan drugs. Front Public Health. 2016;4:214.
Article
PubMed
PubMed Central
Google Scholar
Schey C, Krabbe PFM, Postma MJ, Connolly MP. Multi-criteria decision analysis (MCDA): testing a proposed MCDA framework for orphan drugs. Orphanet J Rare Dis. 2017;12:10.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gilabert-Perramon A, Torrent-Farnell J, Catalan A, Prat A, Fontanet M, Puig-Peiró R, et al. Drug evaluation and decision making in Catalonia: development and validation of a methodological framework based on multi-criteria decision analysis (MCDA) for orphan drugs. Int J Technol Assess Health Care. 2017;33:111.
Article
PubMed
Google Scholar
Inotai A, Brixner D, Maniadakis N, Dwiprahasto I, Kristin E, Prabowo A, et al. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals—an application on improving tender decision making in Indonesia. BMC Health Serv Res. 2018;18:1003.
Article
PubMed
PubMed Central
Google Scholar
Endrei D, Molics B, Agoston I. Multicriteria decision analysis in the reimbursement of new medical technologies: real-world experiences from Hungary. Value Health. 2014;17:487–9.
Article
PubMed
Google Scholar
Suwantika AA, Purwadi FV, Zakiyah N, Puspitasari IM, Abdulah R, Diantini A, et al. Multi-criteria decision analysis to prioritize the introduction of new vaccines in Indonesia by using the framework of the strategic multi-attribute ranking tool for vaccines (SMART Vaccines). Expert Rev Vaccines. 2021.
Botwright S, Kahn AL, Hutubessy R, Lydon P, Biey J, Sidibe AK, et al. How can we evaluate the potential of innovative vaccine products and technologies in resource constrained settings? A total systems effectiveness (TSE) approach to decision-making. Vaccine. 2020;6:100078.
CAS
Google Scholar
De Nardo P, Gentilotti E, Mazzaferri F, Cremonini E, Hansen P, Goossens H, et al. Multi-criteria decision analysis to prioritize hospital admission of patients affected by COVID-19 in low-resource settings with hospital-bed shortage. Int J Infect Dis. 2020;98:494–500.
Article
PubMed
PubMed Central
Google Scholar
Keeney RL, Raiffa H. Decisions with multiple objectives: preferences and value trade-offs. Cambridge: Cambridge University Press; 1993.
Book
Google Scholar
Belton V, Stewart TJ. Multiple criteria decision analysis: an integrated approach. Massachusetts: Kluwer Academic Publishers; 2002.
Book
Google Scholar
Inotai A, Nguyen HT, Hidayat B, Nurgozhin T, Kiet PHT, Campbell JD, et al. Guidance toward the implementation of multicriteria decision analysis framework in developing countries. Expert Rev Pharmacoecon Outcomes Res. 2018;18:585–92.
Article
PubMed
Google Scholar
Wolf JA, Niederhauser V, Marshburn D, LaVela SL. Defining patient experience. Patient Exp. 2014;1:3.
Google Scholar
Pontes C, Fontanet JM, Vives R, Sancho A, Gómez-Valent M, Ríos J, et al. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties. Orphanet J Rare Dis. 2018;13:206.
Article
PubMed
PubMed Central
Google Scholar
Drummond M, Griffin A, Tarricone R. Economic evaluation for devices and drugs—same or different? Value Health. 2009;12:402–4.
Article
PubMed
Google Scholar
Frieden TR. Evidence for health decision making—beyond randomized, controlled trials. N Engl J Med. 2017;377:465–75.
Article
PubMed
Google Scholar
Murray E, Hekler EB, Andersson G, Collins LM, Doherty A, Hollis C, et al. Evaluating digital health interventions: key questions and approaches. Am J Prev Med. 2016;51:843–51.
Article
PubMed
PubMed Central
Google Scholar
Németh B, Kaló Z. European cooperation in health technology assessment implementation: the perspective of Central and Eastern European countries. Future Med. 2020;9:599–602.
Google Scholar
Kristensen FB, Lampe K, Wild C, Cerbo M, Goettsch W, Becla L. The HTA Core Model®—10 years of developing an international framework to share multidimensional value assessment. Value Health. 2017;20:244–50.
Article
PubMed
Google Scholar
EUnetHTA Joint Action 2, Work Package 8. HTA Core Model Version 3.0. 2016. http://www.corehta.info/model/HTACoreModel3.0.pdf. Accessed 18 Mar 2021.
Bodrogi J, Kaló Z. Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. Br J Pharmacol. 2010;159:1367–73.
Article
CAS
PubMed
PubMed Central
Google Scholar
Garrison LP Jr, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, et al. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16:703–19.
Article
PubMed
Google Scholar
Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res. 2013;13:735–41.
Article
PubMed
Google Scholar
Horizon Europe Programme (HORIZON)-Work Programme for Health 2021–2022. 2020. https://efmc.eu/wp-content/uploads/2021/02/Horizon-Europe-Programme-HORIZON-Work-Programme-2021-2022-for-Health-1.pdf. Accessed 18 June 2021.
Torjesen I. Covid-19: Hydroxychloroquine does not benefit hospitalised patients, UK trial finds. BMJ Online. 2020;369:m2263.
Article
PubMed
Google Scholar
Mahase E. Hydroxychloroquine for covid-19: the end of the line? BMJ. 2020;369:m2378.
Article
PubMed
Google Scholar
World Health Organization (WHO). Newsroom. 2020. https://www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19. Accessed 18 Mar 2021.
STAMP Working Group. Draft—proposal for a framework to support not-for-profit organisations in drug repurposing. 2019. https://ec.europa.eu/health/sites/health/files/files/committee/stamp/stamp_11_47_2_en.pdf. Accessed 18 Mar 2021.
Conti RM, Athey S, Frank RG, Gruber J. Generic drug repurposing for public health and national security: COVID-19 and beyond. Health Affairs Blog. 2020. https://www.healthaffairs.org/do/10.1377/hblog20201204.541050/full/. Accessed 18 June 2021.
Godman B, McCabe H, Leong D. Fixed dose drug combinations—are they pharmacoeconomically sound? Findings and implications especially for lower- and middle-income countries. Expert Rev Pharmacoecon Outcomes Res. 2020;20:1–26.
Article
PubMed
Google Scholar